Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05698329 · ClinicalTrials.gov registry record · Phase 1
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by AiViva BioPharma.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 6
- Study locations
NCT05698329: Active Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by AiViva BioPharma.
NCT05698329 is a Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by AiViva BioPharma. The registered enrollment target is 19 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05698329, a Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by AiViva BioPharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 6
- Study locations
Study Summary
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Primary Outcome
Incidence of adverse events and serious adverse events
Conditions Studied
Interventions
- DRUG AIV007
Study Locations (6)
Texas
- Valley Retina Institute - McAllen
- Texas Retina Associates - Plano
- Medical Center Ophthalmology - San Antonio
California
- Retina-Vitreous Associates - Beverly Hills
- Orange County Retina - Santa Ana
Oregon
- Verum Research - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-02 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
What the registry record for NCT05698329 still lists
NCT05698329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which AIV007 is the first listed.
NCT05698329 lists 6 locations in 3 states (Texas, California, Oregon).
Frequently Asked Questions
What is clinical trial NCT05698329 about?
NCT05698329 is a clinical study titled "Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)". To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
What is the current status of trial NCT05698329?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-03-02. Estimated completion is 2025-04-01.
What conditions does trial NCT05698329 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Macular Edema.
What interventions are being tested in trial NCT05698329?
The interventions under investigation include: AIV007 (DRUG).
Who is sponsoring clinical trial NCT05698329?
This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05698329 being conducted?
This trial has 6 study locations across California, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05698329's enrollment target sits among peer trials
19 56th of 63 higher than 8 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI